Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 30

1.

Non-coding RNAs underlie genetic predisposition to breast cancer.

Moradi Marjaneh M, Beesley J, O'Mara TA, Mukhopadhyay P, Koufariotis LT, Kazakoff S, Hussein N, Fachal L, Bartonicek N, Hillman KM, Kaufmann S, Sivakumaran H, Smart CE, McCart Reed AE, Ferguson K, Saunus JM, Lakhani SR, Barnes DR, Antoniou AC, Dinger ME, Waddell N, Easton DF, Dunning AM, Chenevix-Trench G, Edwards SL, French JD.

Genome Biol. 2020 Jan 7;21(1):7. doi: 10.1186/s13059-019-1876-z.

2.

Breast Cancer Heterogeneity in Primary and Metastatic Disease.

Kalinowski L, Saunus JM, McCart Reed AE, Lakhani SR.

Adv Exp Med Biol. 2019;1152:75-104. doi: 10.1007/978-3-030-20301-6_6. Review.

PMID:
31456181
3.

LobSig is a multigene predictor of outcome in invasive lobular carcinoma.

McCart Reed AE, Lal S, Kutasovic JR, Wockner L, Robertson A, de Luca XM, Kalita-de Croft P, Dalley AJ, Coorey CP, Kuo L, Ferguson K, Niland C, Miller G, Johnson J, Reid LE, Males R, Saunus JM, Chenevix-Trench G, Coin L, Lakhani SR, Simpson PT.

NPJ Breast Cancer. 2019 Jun 27;5:18. doi: 10.1038/s41523-019-0113-y. eCollection 2019.

4.

Proteomic Analysis of the Breast Cancer Brain Metastasis Microenvironment.

Kalita-de Croft P, Straube J, Lim M, Al-Ejeh F, Lakhani SR, Saunus JM.

Int J Mol Sci. 2019 May 22;20(10). pii: E2524. doi: 10.3390/ijms20102524.

5.

Innovative Therapeutic Strategies for Effective Treatment of Brain Metastases.

Lim M, Puttick S, Houston ZH, Thurecht KJ, Kalita-de Croft P, Mahler S, Rose SE, Jeffree RL, Mazzieri R, Dolcetti R, Lakhani SR, Saunus JM.

Int J Mol Sci. 2019 Mar 14;20(6). pii: E1280. doi: 10.3390/ijms20061280. Review.

6.

Secreted cellular prion protein binds doxorubicin and correlates with anthracycline resistance in breast cancer.

Wiegmans AP, Saunus JM, Ham S, Lobb R, Kutasovic JR, Dalley AJ, Miranda M, Atkinson C, Foliaki ST, Ferguson K, Niland C, Johnstone CN, Lewis V, Collins SJ, Lakhani SR, Al-Ejeh F, Möller A.

JCI Insight. 2019 Feb 26;5. pii: 124092. doi: 10.1172/jci.insight.124092.

7.

Calcium signalling and breast cancer.

So CL, Saunus JM, Roberts-Thomson SJ, Monteith GR.

Semin Cell Dev Biol. 2019 Oct;94:74-83. doi: 10.1016/j.semcdb.2018.11.001. Epub 2018 Nov 16. Review.

PMID:
30439562
8.

Recent advances in breast cancer research impacting clinical diagnostic practice.

McCart Reed AE, Kalita-De Croft P, Kutasovic JR, Saunus JM, Lakhani SR.

J Pathol. 2019 Apr;247(5):552-562. doi: 10.1002/path.5199. Epub 2019 Jan 16. Review.

PMID:
30426489
9.

Breast cancer metastasis to gynaecological organs: a clinico-pathological and molecular profiling study.

Kutasovic JR, McCart Reed AE, Males R, Sim S, Saunus JM, Dalley A, McEvoy CR, Dedina L, Miller G, Peyton S, Reid L, Lal S, Niland C, Ferguson K, Fellowes AP, Al-Ejeh F, Lakhani SR, Cummings MC, Simpson PT.

J Pathol Clin Res. 2019 Jan;5(1):25-39. doi: 10.1002/cjp2.118. Epub 2018 Oct 22.

10.

CEP55 is a determinant of cell fate during perturbed mitosis in breast cancer.

Kalimutho M, Sinha D, Jeffery J, Nones K, Srihari S, Fernando WC, Duijf PH, Vennin C, Raninga P, Nanayakkara D, Mittal D, Saunus JM, Lakhani SR, López JA, Spring KJ, Timpson P, Gabrielli B, Waddell N, Khanna KK.

EMBO Mol Med. 2018 Sep;10(9). pii: e8566. doi: 10.15252/emmm.201708566.

11.

Characterization of a novel breast cancer cell line derived from a metastatic bone lesion of a breast cancer patient.

Johnson J, Bessette DC, Saunus JM, Smart CE, Song S, Johnston RL, Cocciardi S, Rozali EN, Johnstone CN, Vargas AC, Kazakoff SH, BioBank VC, Khanna KK, Lakhani SR, Chenevix-Trench G, Simpson PT, Nones K, Waddell N, Al-Ejeh F.

Breast Cancer Res Treat. 2018 Jul;170(1):179-188. doi: 10.1007/s10549-018-4719-9. Epub 2018 Feb 21.

PMID:
29468485
12.

Expression of MAGE-A and NY-ESO-1 cancer/testis antigens is enriched in triple-negative invasive breast cancers.

Raghavendra A, Kalita-de Croft P, Vargas AC, Smart CE, Simpson PT, Saunus JM, Lakhani SR.

Histopathology. 2018 Jul;73(1):68-80. doi: 10.1111/his.13498. Epub 2018 Apr 14.

13.

Mixed ductal-lobular carcinomas: evidence for progression from ductal to lobular morphology.

McCart Reed AE, Kutasovic JR, Nones K, Saunus JM, Da Silva L, Newell F, Kazakoff S, Melville L, Jayanthan J, Vargas AC, Reid LE, Beesley J, Chen XQ, Patch AM, Clouston D, Porter A, Evans E, Pearson JV, Chenevix-Trench G, Cummings MC, Waddell N, Lakhani SR, Simpson PT.

J Pathol. 2018 Apr;244(4):460-468. doi: 10.1002/path.5040. Epub 2018 Mar 9.

14.

Multidimensional phenotyping of breast cancer cell lines to guide preclinical research.

Saunus JM, Smart CE, Kutasovic JR, Johnston RL, Kalita-de Croft P, Miranda M, Rozali EN, Vargas AC, Reid LE, Lorsy E, Cocciardi S, Seidens T, McCart Reed AE, Dalley AJ, Wockner LF, Johnson J, Sarkar D, Askarian-Amiri ME, Simpson PT, Khanna KK, Chenevix-Trench G, Al-Ejeh F, Lakhani SR.

Breast Cancer Res Treat. 2018 Jan;167(1):289-301. doi: 10.1007/s10549-017-4496-x. Epub 2017 Sep 9.

PMID:
28889351
15.

Breast Cancer Brain Metastases: Clonal Evolution in Clinical Context.

Saunus JM, McCart Reed AE, Lim ZL, Lakhani SR.

Int J Mol Sci. 2017 Jan 13;18(1). pii: E152. doi: 10.3390/ijms18010152. Review.

16.

'Omics Approaches in Breast Cancer Research and Clinical Practice.

Kalita-de Croft P, Al-Ejeh F, McCart Reed AE, Saunus JM, Lakhani SR.

Adv Anat Pathol. 2016 Nov;23(6):356-367. Review.

PMID:
27740960
17.

SASH1 mediates sensitivity of breast cancer cells to chloropyramine and is associated with prognosis in breast cancer.

Burgess JT, Bolderson E, Saunus JM, Zhang SD, Reid LE, McNicol AM, Lakhani SR, Cuff K, Richard K, Richard DJ, O'Byrne KJ.

Oncotarget. 2016 Nov 8;7(45):72807-72818. doi: 10.18632/oncotarget.12020.

18.

Long-range regulators of the lncRNA HOTAIR enhance its prognostic potential in breast cancer.

Milevskiy MJ, Al-Ejeh F, Saunus JM, Northwood KS, Bailey PJ, Betts JA, McCart Reed AE, Nephew KP, Stone A, Gee JM, Dowhan DH, Dray E, Shewan AM, French JD, Edwards SL, Clark SJ, Lakhani SR, Brown MA.

Hum Mol Genet. 2016 Aug 1;25(15):3269-3283. doi: 10.1093/hmg/ddw177. Epub 2016 Jul 4.

19.

The calcium pump plasma membrane Ca(2+)-ATPase 2 (PMCA2) regulates breast cancer cell proliferation and sensitivity to doxorubicin.

Peters AA, Milevskiy MJ, Lee WC, Curry MC, Smart CE, Saunus JM, Reid L, da Silva L, Marcial DL, Dray E, Brown MA, Lakhani SR, Roberts-Thomson SJ, Monteith GR.

Sci Rep. 2016 May 5;6:25505. doi: 10.1038/srep25505.

20.

Novel highly specific anti-periostin antibodies uncover the functional importance of the fascilin 1-1 domain and highlight preferential expression of periostin in aggressive breast cancer.

Field S, Uyttenhove C, Stroobant V, Cheou P, Donckers D, Coutelier JP, Simpson PT, Cummings MC, Saunus JM, Reid LE, Kutasovic JR, McNicol AM, Kim BR, Kim JH, Lakhani SR, Neville AM, Van Snick J, Jat PS.

Int J Cancer. 2016 Apr 15;138(8):1959-70. doi: 10.1002/ijc.29946. Epub 2015 Dec 21.

Supplemental Content

Loading ...
Support Center